Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 176.

https://doi.org/10.1182/blood.V128.22.176.176

Published: 2016

Journal Articles

Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Blood (2015) 126 (23): 4374.

https://doi.org/10.1182/blood.V126.23.4374.4374

Published: 2015

Journal Articles

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte ® ) In Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2013) 122 (21): 3901.

https://doi.org/10.1182/blood.V122.21.3901.3901

Published: 2013

Journal Articles

The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation

Tamara Intermesoli, MD, Marco Frigeni, MD, Elena Oldani, BiolSC, Pamela Zanghì, BiolSC, Orietta Spinelli, BiolSC, Alberto Bosi, MD, Filippo Marmont, MD, Giuseppe Rossi, Sergio Cortelazzo, MD, Alessandro Levis, Daniele Mattei, MD, Maria Pogliani Enrico Maria, MD, Anna Maria Scattolin, MD, Massimo Bernardi, MD, Giacomo Gianfaldoni, MD, Ernesta Audisio, MD, Arianna Masciulli, BiolSc, Renato Bassan, MD, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 2648.

https://doi.org/10.1182/blood.V122.21.2648.2648

Published: 2013

Journal Articles

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

Blood (2012) 120 (21): 1494.

https://doi.org/10.1182/blood.V120.21.1494.1494

Published: 2012

Journal Articles

In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome

Tamara Intermesoli, MD, Chiara Cattaneo, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Claudio Romani, MD, Vincenzo Cassibba, MD, Agostino Cortelezzi, MD, Francesco Mannelli, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Orietta Spinelli, BiolSC, Manuela Tosi, BiolSC, Elena Oldani, BiolSC, Alessandro Rambaldi, MD, Renato Bassan, MD

Blood (2012) 120 (21): 662.

https://doi.org/10.1182/blood.V120.21.662.662

Published: 2012

Journal Articles

Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BiolSC, Elena Oldani, BiolSC, Manuela Tosi, BiolSC, Barbara Peruta, BiolSC, Erika Borlenghi, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Vincenzo Cassibba, MD, Anna Maria Scattolin, MD, Claudio Romani, MD, Fabio Ciceri, MD, Agostino Cortelezzi, MD, Giacomo Gianfaldoni, MD, Daniele Mattei, MD, Ernesta Audisio, MD, Tamara Intermesoli, Alessandro Rambaldi, MD

Blood (2012) 120 (21): 2573.

https://doi.org/10.1182/blood.V120.21.2573.2573

Published: 2012

Journal Articles

In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.

Blood (2012) 120 (21): 2493.

https://doi.org/10.1182/blood.V120.21.2493.2493

Published: 2012

Journal Articles

Improved Clinical Outcome of Adult Patients with Ph+ ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group

Blood (2010) 116 (21): 682.

https://doi.org/10.1182/blood.V116.21.682.682

Published: 2010

Journal Articles

Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07

Blood (2010) 116 (21): 2131.

https://doi.org/10.1182/blood.V116.21.2131.2131

Published: 2010

Journal Articles

Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Blood (2009) 114 (22): 2029.

https://doi.org/10.1182/blood.V114.22.2029.2029

Published: 2009

Journal Articles

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Blood (2009) 113 (18): 4153–4162.

https://doi.org/10.1182/blood-2008-11-185132

Published: 2009

Includes: Supplemental data

Journal Articles

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Blood (2009) 113 (14): 3375–3382.

https://doi.org/10.1182/blood-2008-07-167379

Published: 2009

Journal Articles

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Barbara Peruta, BSc, Vittoria Guerini, BSc, Giuseppe Rossi, MD, Enrico Pogliani, MD, Eros Di Bona, MD, Pietro Fabris, MD, Agostino Cortelezzi, MD, Teodoro Chisesi, MD, Emanuele Angelucci, MD, Franco Leoni, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 3497.

https://doi.org/10.1182/blood.V110.11.3497.3497

Published: 2007

Journal Articles

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Giuseppe Rossi, MD, Enrico M. Pogliani, MD, Emanuele Angelucci, MD, Pietro Fabris, MD, Giorgio Lambertenghi-Deliliers, MD, Paola Polistena, MD, Eros Di Bona, MD, Fabio Ciceri, MD, Franco Leoni, MD, Claudia Minotto, MD, Daniele Mattei, MD, Maurizio Musso, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2005) 106 (11): 1836.

https://doi.org/10.1182/blood.V106.11.1836.1836

Published: 2005

Journal Articles

Telomerase and Telomeres in Polycythemia Vera and Essential Thrombocythemia.

Andrea Gallamini, Anna Maria Ferraris, Daniele Mattei, Natalija Pujic, Rosa Mangerini, Davide Rapezzi, Sivia Tavera, Gian Franco Gaetani

Blood (2005) 106 (11): 4948.

https://doi.org/10.1182/blood.V106.11.4948.4948

Published: 2005

Journal Articles

Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospectic Multicenter Study.

Nicola Mordini, MD, Benedetto Bruno, MD, Alessandro Busca, MD, Roberto Sorasio, MD, Mario Boccadoro, PHD, Eugenio Gallo, PHD, Andrea Gallamini, MD, Daniele Mattei, MD

Blood (2004) 104 (11): 5057.

https://doi.org/10.1182/blood.V104.11.5057.5057

Published: 2004

Journal Articles

T/NK “Nasal Type” Lymphomas: An Italian Cooperative Retrospective Survey.

Livio Pagano, MD, Andrea Gallamini, MD, Giulio Trapè, MD, Daniele Mattei, MD, Eros Di Bona, MD, Emilio Iannitto, MD, Antonio Spadea, MD, Elena Rossi, MD, Raffaele Tartaglione, MD, Maurizio Martelli, MD, Anna Maria Nosari, MD, Concetta Petti, MD, Paolo Falcucci, MD, Luigi Maria Larocca, MD, Giuseppe Leone, MD

Blood (2004) 104 (11): 4578.

https://doi.org/10.1182/blood.V104.11.4578.4578

Published: 2004

Journal Articles

Risk Factors of Cytomegalovirus Infection in Autologous Stem Cell Transplantation (ASCT).

Margherita Bonferroni, Mariella Grasso, Silvia Tavera, Roberta Calvi, Daniele Mattei, Maria A. Pistone, Andrea Gallamini

Blood (2004) 104 (11): 5219.

https://doi.org/10.1182/blood.V104.11.5219.5219

Published: 2004

Journal Articles

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

Andrea Gallamini, Caterina Stelitano, Roberta Calvi, Monica Bellei, Daniele Mattei, Umberto Vitolo, Fortunato Morabito, Maurizio Martelli, Ercole Brusamolino, Emilio Iannitto, Francesco Zaja, Sergio Cortelazzo, Luigi Rigacci, Liliana Devizzi, Giuseppe Todeschini, Gino Santini, Maura Brugiatelli, Massimo Federico, for the Intergruppo Italiano Linfomi

Blood (2004) 103 (7): 2474–2479.

https://doi.org/10.1182/blood-2003-09-3080

Published: 2004

NARROW

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Levels of Minimal Residual Disease Prior to Transplant Influence Outcome of Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte ® ) In Adult Acute Lymphoblastic Leukemia (ALL)

The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome

Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.

Improved Clinical Outcome of Adult Patients with Ph+ ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group

Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07

Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Minimal Residual Disease (MRD) and Risk-Oriented Therapy in Adult Acute Lymphoblastic Leukemia (ALL).

Telomerase and Telomeres in Polycythemia Vera and Essential Thrombocythemia.

Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospectic Multicenter Study.

T/NK “Nasal Type” Lymphomas: An Italian Cooperative Retrospective Survey.

Risk Factors of Cytomegalovirus Infection in Autologous Stem Cell Transplantation (ASCT).

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only